Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis

被引:42
作者
Shih, Ie-Ming [1 ,2 ,3 ]
Chen, Li [4 ]
Wang, Chen C. [4 ]
Gu, Jinghua [4 ]
Davidson, Ben [5 ,6 ]
Cope, Leslie [2 ,3 ]
Kurman, Robert J. [1 ,2 ,3 ]
Xuan, Jianhua [4 ]
Wang, Tian-Li [2 ,3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Gynecol Pathol, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21231 USA
[4] Virginia Polytech Inst & State Univ, Bradley Dept Elect & Comp Engn, Arlington, VA USA
[5] Oslo Univ Hosp, Norwegian Radium Hosp, Div Pathol, Oslo, Norway
[6] Univ Oslo, Fac Div Radiumhosp, Oslo, Norway
基金
美国国家卫生研究院;
关键词
methylation; ovarian carcinoma; INDEPENDENT PROGNOSTIC-FACTOR; PROMOTER METHYLATION; LOW-GRADE; BORDERLINE TUMORS; CANCER; HYPERMETHYLATION; GENE; MUTATIONS; PATHOGENESIS; SUPPRESSOR;
D O I
10.1016/j.ajog.2010.08.003
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The purpose of this study was to analyze DNA methylation profiles among different types of ovarian serous neoplasm, which is a task that has not been performed. STUDY DESIGN: The Illumina beads array (Illumina Inc, San Diego, CA) was used to profile DNA methylation in enriched tumor cells that had been isolated from 75 benign and malignant serous tumor tissues and 6 tumor-associated stromal cell cultures. RESULTS: We found significantly fewer hypermethylated genes in high-grade serous carcinomas than in low-grade serous carcinoma and borderline tumors, which in turn had fewer hypermethylated genes than serous cystadenoma. Unsupervised analysis identified that serous cystadenoma, serous borderline tumor, and low-grade serous carcinomas tightly clustered together and were clearly different from high-grade serous carcinomas. We also performed supervised analysis to identify differentially methylated genes that may contribute to group separation. CONCLUSION: The findings support the view that low-grade and high-grade serous carcinomas are distinctly different with low-grade, but not high-grade, serous carcinomas that are related to serous borderline tumor and cystadenoma.
引用
收藏
页码:584.e1 / 584.e22
页数:22
相关论文
共 34 条
  • [1] DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment
    Barton, Caroline A.
    Hacker, Neville F.
    Clark, Susan. J.
    O'Brien, Philippa A.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 109 (01) : 129 - 139
  • [2] Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
    Baylin, SB
    Ohm, JE
    [J]. NATURE REVIEWS CANCER, 2006, 6 (02) : 107 - 116
  • [3] Ovarian Cancer
    Cho, Kathleen R.
    Shih, Ie-Ming
    [J]. ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 : 287 - 313
  • [4] Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas
    Choi, YL
    Kang, SY
    Choi, JK
    Shin, YS
    Kim, SH
    Lee, SJ
    Bae, DS
    Ahn, G
    [J]. VIRCHOWS ARCHIV, 2006, 448 (03) : 331 - 336
  • [5] Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer
    Chou, Jian-Liang
    Su, Her-Young
    Chen, Lin-Yu
    Liao, Yu-Ping
    Hartman-Frey, Corinna
    Lai, Yi-Hui
    Yang, Hui-Wen
    Deatherage, Daniel E.
    Kuo, Chieh-Ti
    Huang, Yi-Wen
    Yan, Pearlly S.
    Hsiao, Shu-Huei
    Tai, Chien-Kuo
    Lin, Huey-Jen L.
    Davuluri, Ramana V.
    Chao, Tai-Kuang
    Nephew, Kenneth P.
    Huang, Tim H-M
    Lai, Hung-Cheng
    Chan, Michael W-Y
    [J]. LABORATORY INVESTIGATION, 2010, 90 (03) : 414 - 425
  • [6] The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma - A morphogic and molecular genetic analysis
    Dehari, Reiko
    Kurman, Robert J.
    Logani, Sanjay
    Shih, Ie-Ming
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (07) : 1007 - 1012
  • [7] DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma
    Feng, Qinghua
    Deftereos, Georgicis
    Hawes, Stephen E.
    Stern, Joshua E.
    Willner, Julia B.
    Swisher, Elizabeth M.
    Xi, Longfu
    Drescher, Charles
    Urban, Nicole
    Kiviat, Nancy
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 111 (02) : 320 - 329
  • [8] HOXA11 DNA methylation -: A novel prognostic biomarker in ovarian cancer
    Fiegl, Heidi
    Windbichler, Gudrun
    Mueller-Holzner, Elisabeth
    Goebel, Georg
    Lechner, Matthias
    Jacobs, Ian J.
    Widschwendter, Martin
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (03) : 725 - 729
  • [9] Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
    Herman, JG
    Baylin, SB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) : 2042 - 2054
  • [10] Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors
    Ho, CL
    Karman, RJ
    Dehari, R
    Wang, TL
    Shih, LM
    [J]. CANCER RESEARCH, 2004, 64 (19) : 6915 - 6918